Jin Medical Signs $159M VIE Acquisition for Ginseng Tech Assets, Issuing 71.3M Shares
ZJYL sits 32% above its 52-week low of $1.53.
Summary
Jin Medical signed a $159.4 million VIE acquisition of ginseng research assets, issuing 71.3 million Class A shares plus 8.5 million advisor shares — a highly dilutive deal for a pre-revenue target.
Key Events · M&A and Partnerships · ZJYL
-
New $159.4M VIE Acquisition Signed
Jin Medical entered a VIE Control Master Acquisition Agreement on September 8, 2026, to acquire contractual control of Huaxia Qiying (Beijing) Technology Co., Ltd., which holds ginseng-related biological assets and the KB-120 fermentation technology platform. Aggregate consideration is US$159,415,729.
-
71.3M Shares Issued as Consideration
The company will issue 71,282,488 Class A ordinary shares to the seller's designees, plus 8,479,560 shares to financial advisor Veltrion Haskel Holdings Limited and its designee at US$1.88 per share — a total of 79.8 million new shares.
-
Target Has No Commercial Business
Huaxia Qiying does not currently operate an established commercial business; its assets are ginseng biological resources and research results intended to support future commercialization. The acquisition is for pre-revenue research assets.
-
Second Major Dilutive Deal in Two Months
This follows the $105 million Beijing Tongsheng VIE acquisition closed on August 4, 2026, which issued 70.6 million shares. Combined, the two deals represent approximately 150 million new shares against a market cap of roughly $158 million.
Analysis · ZJYL · Industrial Applications And Services
Jin Medical has entered into a second major VIE acquisition in under two months, this time for Huaxia Qiying's ginseng-related biological and research assets at a $159.4 million valuation. The deal is paid almost entirely in newly issued Class A shares — 71.3 million to the seller's designees plus 8.5 million to the financial advisor — representing a highly dilutive transaction for a company with a market cap of roughly $158 million. The target has no established commercial business, so shareholders are being asked to absorb massive dilution for pre-revenue research assets. This follows the $105 million Beijing Tongsheng acquisition closed on August 4, 2026, which already issued 70.6 million shares, suggesting an aggressive roll-up strategy funded entirely by equity issuance.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZJYL was trading at $2.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $158.4M. The 52-week trading range was $1.53 to $14.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.